Cargando…

Abstract 5: Similar hypoglycemia duration with once-weekly insulin icodec versus insulin glargine U100 in insulin naïve or experienced patients with T2D

Insulin icodec* (icodec) is a novel once-weekly basal insulin analog in development. This post hoc analysis explored hypoglycemia duration using double-blinded CGM (Dexcom G6(®)) data from 2 phase 2, randomized, open-label, treat-to-target 16-week trials. One trial compared 3 titration algorithms of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Manjunath, Aparna, Silver, Robert J, Asong, Marisse, Begtrup, Kamilla, Koefoed, Mette M, Heller, Simon R, Rosenstock, Julio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2022
Materias:	Abstracts … Esicon 2021
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9067734/ http://dx.doi.org/10.4103/2230-8210.342306

Ejemplares similares

Abstract 3: CGM-derived parameters for once-weekly insulin icodec versus once-daily insulin glargine U100 in insulin-Naïve patients with T2D
por: Kunder, Sushil, et al.
Publicado: (2022)

Abstract 141: CGM-based measurements for once-weekly insulin icodec versus once-daily insulin glargine U100 in insulin-treated patients with type 2 diabetes: A post hoc analysis
por: Chandrappa, Manu, et al.
Publicado: (2022)

A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100
por: Lingvay, Ildiko, et al.
Publicado: (2021)

Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial
por: Bajaj, Harpreet S., et al.
Publicado: (2021)

Rationale and design of the phase 3a development programme (ONWARDS 1–6 trials) investigating once‐weekly insulin icodec in diabetes
por: Philis‐Tsimikas, Athena, et al.
Publicado: (2022)

Abstract 160: A tri prong approach in the management of insulin autoimmune syndrome
por: Kumar, N S Praveen, et al.
Publicado: (2022)

Abstract 21: The burden of mealtime insulin dosing in adults and children with type 1 diabetes
por: Revanna, Manjunatha, et al.
Publicado: (2022)

Abstract 28: Change in glycaemic parameters in adults with type 2 diabetes initiated with or switched to insulin degludec/insulin aspart (IDegAsp) in a real-world setting – An analysis of Indian cohort of ARISE study
por: Baruah, Manash P, et al.
Publicado: (2022)

Abstract 49: Insulin resistance syndrome presenting with diabetic ketoacidosis – A rare case presentation
por: Kaur, Kirandeep, et al.
Publicado: (2022)

Abstract 123: Insulin resistance syndrome presenting with diabetic ketoacidosis – A rare case presentation
por: Kaur, Kirandeep, et al.
Publicado: (2022)

Abstract 17: Spontaneous hypoglycaemia due to insulin autoimmune syndrome in five cases, response to steroid therapy and rituximab
por: Batra, C M, et al.
Publicado: (2022)

Abstract 10: Efficacy and safety of semaglutide 2.4 mg once- weekly in adults with overweight or obesity and type 2 diabetes (STEP 2)
por: Rahman, Syed Kasfur, et al.
Publicado: (2022)

Abstract 120: Prevalence of hypogonadism in men with type 2 diabetes mellitus and its association with insulin resistance, metabolic and clinical parameters
por: Singh, Jaspreet, et al.
Publicado: (2022)

Once-Weekly Insulin Icodec vs. Once-Daily Insulin Glargine U100 for type 2 diabetes: a systematic review and meta-analysis of phase 2 randomized controlled trials
por: Silva, Rodrigo Ribeiro e, et al.
Publicado: (2023)

Abstract 153: Bone microarchitecture, bone mineral density and bone turnover in association with glycemia and insulin action in women with prior gestational diabetes
por: Kubihal, Suraj, et al.
Publicado: (2022)

Abstract 119: Management of newly diagnosed type 2 diabetes mellitus with HBA1C > 10% in patients reluctant to take insulin
por: Panikar, Krish, et al.
Publicado: (2022)

Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing
por: Nishimura, Erica, et al.
Publicado: (2021)

Abstract 63: A case report of friedreich ataxia (FA) associated with diabetes mellitus and hypertrophic cardiomyopathy “A tri prong approach in the management of insulin autoimmune syndrome”
por: Kumar, N S Praveen, et al.
Publicado: (2022)

Hypoglycaemia frequency and physiological response after double or triple doses of once-weekly insulin icodec vs once-daily insulin glargine U100 in type 2 diabetes: a randomised crossover trial
por: Pieber, Thomas R., et al.
Publicado: (2023)

Abstract 62: Relative contribution of insulin resistance and beta cell dysfunction in subjects with metabolic syndrome and new onset diabetes, as assessed by HOMA 2: A comparative analysis from a South Indian cohort
Publicado: (2022)

Insulin Icodec Weekly: A Basal Insulin Analogue for Type 2 Diabetes
por: Bajaj, Harpreet S, et al.
Publicado: (2023)

Abstract 9: Once-weekly subcutaneous semaglutide 2.4 mg reduces body weight in adults with overweight or obesity regardless of baseline characteristics (STEP 1)
por: Suresh, Swaroop H, et al.
Publicado: (2022)

Abstract 155: Vitamin D dependent rickets type II: Our experience and systematic review
por: Manjunath,
Publicado: (2022)

Insulin Detemir Versus Insulin Glargine in the Hospital: Do Hypoglycemia Rates Differ?
por: Crisher, Michelle A., et al.
Publicado: (2019)

Abstract 34: Time spent in glycemic control after initiating treatment with oral semaglutide versus empagliflozin: An exploratory analysis of the PIONEER 2 trial
por: Prakash, Prashanth S, et al.
Publicado: (2022)

Abstract 82: Rare case of 46XY OVO testicular DSD
por: Naushad, Altaf Ali, et al.
Publicado: (2022)

Insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia?
por: Buscemi, Silvio, et al.
Publicado: (2019)

LBSUN210 Efficacy And Safety Profile Of Insulin Icodec Versus Insulin Glargine U100 In Type 2 Diabetes Mellitus: A Meta-Analysis Of Randomized Controlled Trials
por: Dimayuga, Diana Colleen, et al.
Publicado: (2022)

Response to insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia?
por: Yamabe, Mizuho
Publicado: (2019)

D1 MTE1 Case 1: Steroid refractory insulin autoimmune syndrome treated with rituximab and continuous glucose monitoring
por: Batra, Chandar M, et al.
Publicado: (2022)

The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily: A 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes
por: Meneghini, Luigi, et al.
Publicado: (2013)

A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin–Treated Patients With Type 2 Diabetes
por: Bergenstal, Richard M., et al.
Publicado: (2012)

Insulin glargine overdose
por: Doğan, Fatma Sarı, et al.
Publicado: (2012)

Efficacy and safety of once‐daily insulin degludec/insulin aspart compared with once‐daily insulin glargine in participants with Type 2 diabetes: a randomized, treat‐to‐target study
por: Kumar, S., et al.
Publicado: (2016)

Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus
por: Linnebjerg, Helle, et al.
Publicado: (2016)

Abstract 150: Whole exome sequencing of siblings identifies a novel variant p.A399fs in ANOS1 gene associated with Kallman syndrome
por: Sahlot, Rahul
Publicado: (2022)

Abstract 18: Circulating cell free long-noncoding RNA (PVT1 and MALAT1) expression in determining malignancy in indeterminate category of thyroid nodules
por: Dutta, Susmita, et al.
Publicado: (2022)

Abstract 135: A case of acquired Gitelman syndrome presenting as hypokalemic paralysis and AKI
por: Pradhan, Amrita
Publicado: (2022)

Abstract 43: Prevalence of islet-autoantibodies and monogenic diabetes in children with recent onset type 1 diabetes mellitus: A multicenter study
por: Jayakrishnan, C, et al.
Publicado: (2022)

Abstract 91: ACTH stimulated salivary cortisol is a better indicator of adrenal insufficiency compared to stimulated serum cortisol in subjects with cirrhosis liver
por: Karthik, V, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5jrsrd5rf81drjaibptu76phd3